注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Erasca Inc是一家临床阶段精准肿瘤学公司。该公司专注于发现、开发和商业化针对RAS/MAPK通路驱动的癌症的疗法。该公司从事肿瘤学和RAS靶向治疗,以创建旨在全面关闭RAS/MAPK通路以治疗癌症的疗法和组合方案。该公司的主要候选产品是ERAS-007和ERAS-601,它们共同构成了其第一个MAPKlamp。ERAS-007被设计为ERK1/2的口服抑制剂,已在Asana完成的晚期实体瘤患者的I期临床试验中作为单一药物进行了评估。ERAS-601是一种口服SHP2抑制剂,目前正在进行人体I期临床试验FLAGSHP-1。该公司的SHP2抑制剂旨在阻断致癌信号转导并延缓治疗耐药性的发生,这有可能成为针对RAS/MAPK通路改变的癌症的联合治疗的支柱。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Pratik S. Multani | 57 | 2018 | Independent Director |
Valerie Harding-Start | 64 | 2019 | Independent Director |
James A. Bristol | 77 | 2018 | Independent Director |
John Lo | - | 2022 | Senior Commercial Advisor & Member of Research, Development and Commercial Advisory Board |
Alexander Whitman Casdin | 56 | 2018 | Independent Director |
Julie Hambleton | 66 | 2021 | Independent Director |
Karen Cichowski | - | - | Scientific Advisory Board Member |
Pablo Rodriguez-Viciana | - | - | Scientific Advisory Board Member |
Bruce D. Roth | - | - | Member of R&D Advisory Board |
Linda Robertson | - | - | Member of R&D Advisory Board |
Kevan M. Shokat | - | - | Scientific Advisory Board Member |
Jonathan E. Lim | 52 | 2018 | Co-Founder, Chairman & CEO |
Gregory Cosma | - | - | Member of R&D Advisory Board |
David Matthews | 81 | - | Member of R&D Advisory Board |
Paul G. Pearson | 63 | - | Member of R&D Advisory Board |
James L. Freddo | 69 | - | Member of R&D Advisory Board |
Ryan B. Corcoran | - | - | Scientific Advisory Board Member |
George Daniel Demetri | 67 | - | Scientific Advisory Board Member |
Stephen C. Blacklow | - | - | Scientific Advisory Board Member |
Jane Chang | - | - | Member of R&D Advisory Board |
Jean I. Liu | 56 | 2022 | Independent Director |
Michael D. Varney | 66 | 2020 | Chairman of Research & Development, Scientific Advisory Board Member and Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核